Merus, the Healthcare sector company, was revisited by a Wall Street analyst on August 6. Analyst Andrew Berens from Leerink Partners maintained a Buy rating on the stock and has a $95.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors related to Merus’s recent financial and clinical developments. The company has shared its second-quarter financial results and provided updates on its pipeline, which includes promising progress in their clinical trials. The ongoing trials for petosemtamab in head and neck squamous cell carcinoma (HNSCC) are expected to be substantially enrolled by the end of 2025, with interim results anticipated in 2026. Additionally, Merus is on track for a clinical data update for metastatic colorectal cancer (mCRC) in the second half of 2025, which could serve as a significant catalyst for the stock.
Merus’s management has indicated that the outcomes of these trials, particularly if they outperform existing benchmarks, could drive decisive strategic decisions. The company’s financial position is also strong, with substantial cash reserves expected to support its operations. These factors, combined with the potential for strategic partnerships, underpin Berens’s optimistic outlook and Buy rating for Merus’s stock.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $67.00 price target.